

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistical parameters

When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).

n/a | Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
- Clearly defined error bars
State explicitly what error bars represent (e.g. SD , SE , CI)

Our web collection on [statistics for biologists](#) may be useful.

Software and code

Policy information about [availability of computer code](#)

Data collection

BD Accuri C6 Software v1.0.264.21
Bio-Rad CFX Manager 3.1
ImageStudio 5.2

Data analysis

FloJo 10
Prism 5.0
Geneious 8.2.11
Bio-Rad CFX Manager 3.1
Mesquite 3.4
FigTree v1.4.3
RAxML 8.2.11
ImageStudio 5.2

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All data needed to evaluate the conclusions in the paper are present in the paper or in the supplementary table. The plasmids described in Supplementary Table 1, along with their complete nucleotide sequences, are available at https://www.addgene.org/Jeremy_Luban/.

Field-specific reporting

Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/authors/policies/ReportingSummary-flat.pdf](https://www.nature.com/authors/policies/ReportingSummary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| | |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sample size | No sample size calculation was performed. Experiments were repeated a multiple of at least three times. We expected large effects and in standard molecular biology experiments, with a prediction of this sort, we usually start with 3 biological replicates and test the statistics. In all cases, the effects were very large and reproducible and did not require more complex size calculations. |
| Data exclusions | No data was excluded from analysis. |
| Replication | All attempts at replication were successful. GFP reporter assays were repeated at least 3 times independently. Stable knockdown cells or cells overexpressing VPX/R were established multiple times and tested for transactivating activity with reporter vectors. Spreading infections were repeated at least 3 times each, data from individual replicates was normalized to maximum infection observed and area under the curve was calculated for statistical comparisons. |
| Randomization | There was no randomization for experiments. Randomization is not customary for standard molecular biology experiments such as these. |
| Blinding | Investigators were not blinded to group allocation during data collection and or analysis. Outcomes were very clear, large in effect, and highly reproducible. |

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

| | |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study description | Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study). |
| Research sample | State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source. |
| Sampling strategy | Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed. |
| Data collection | Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection. |
| Timing | Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort. |
| Data exclusions | If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established. |
| Non-participation | State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation. |

Randomization

If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.

Research sample

Describe the research sample (e.g. a group of tagged *Passer domesticus*, all *Stenocereus thurberi* within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.

Sampling strategy

Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.

Data collection

Describe the data collection procedure, including who recorded the data and how.

Timing and spatial scale

Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken

Data exclusions

If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.

Reproducibility

Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.

Randomization

Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.

Blinding

Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.

Did the study involve field work? Yes No

Field work, collection and transport

Field conditions

Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).

Location

State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).

Access and import/export

Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).

Disturbance

Describe any disturbance caused by the study and how it was minimized.

Reporting for specific materials, systems and methods

Materials & experimental systems

- | | |
|-------------------------------------|-----------------------------------------------------------------|
| n/a | Included in the study |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Unique biological materials |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Antibodies |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Animals and other organisms |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Human research participants |

Methods

- | | |
|-------------------------------------|----------------------------------------------------|
| n/a | Included in the study |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Flow cytometry |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |

Unique biological materials

Policy information about [availability of materials](#)

Obtaining unique materials All plasmids engineered here are listed in Table 1 and will be available from Addgene, along with the full plasmid sequences.

Antibodies

Antibodies used

anti-FAM208a (Atlas, HPA006735 lot A906822),
anti-MPP8 (Proteintech, 16796-1-AP),
anti-PPHLN1 (Sigma, HPA038902, A104626),
anti-DCAF1 (Proteintech, 11612-1-AP),
anti-FLAG (Novus, NB600-345, lot A9),
anti-FLAG (Sigma, F1804, lot SCBT7654),
anti-HA (Biolegend, 901501, lot B242906),
anti-MORC2 (Bethyl Labs, A300-149A)
anti-LINE1 ORF1p (Millipore, MABC1152)
secondary goat anti-mouse IRDye 680RD (Licor, 925-68070)
secondary goat anti-rabbit IRDye 800CW (Licor, 925-32211)
anti-Actin (Abcam, AB3280),
anti-CD28 (clone CD28.2) and anti-CD3 (clone OKT3) were provided by Lisa Cavacini (MassBiologics)

Validation

Antibodies utilized were validated by vendor by western blotting cell lysates expressing the antigen and validation is available on their websites. FAM208a, MPP8, PPHLN1, MORC2 and DCAF1 antibodies were also shown specific in our studies in comparison to respective knockdown cell lines (Supplemental Figures 2b and Fig 2g). LINE1 ORF1p was validated in our lab by positive staining in cells known to express LINE1 elements and negative in cells known not to express them. Anti-CD3 and anti-CD28 antibodies were validated by surface FACS staining and induction of proliferative T-cell response.

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)

Jurkat clone E6-1, CEMx174, NTERA-2 D1, and HEK293 cells were acquired from ATCC . J-Lat A1 cells were obtained from NIH AIDS Reagent Program.

Authentication

Cells acquired from ATCC were authenticated by the vendor using morphology, karyotyping, and PCR based approaches. J-Lat A1 lines from NIH were checked for described morphology, growth in suspension, and low GFP expression.

Mycoplasma contamination

Cell lines used in this study were tested negative for mycoplasma. (MycoAlert, Lonza)

Commonly misidentified lines
(See [ICLAC](#) register)

No commonly misidentified cell lines were utilized in this study.

Palaeontology

Specimen provenance

Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).

Specimen deposition

Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods

If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals

For laboratory animals, report species, strain, sex and age OR state that the study did not involve laboratory animals.

Wild animals

Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.

Field-collected samples

For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

For flow cytometry cells were fixed in BD Cytofix prior to acquisition on BD Accuri C6.

Instrument

BD Accuri C6

Software

BD Accuri C6 Software v1.0.264.21 was utilized to collect Flow cytometry data

Cell population abundance

For purity of CD4+ cells, cells were stained for CD3 and CD4 after MACS enrichment.

Gating strategy

Lymphocytes were gated by FSCxSSC. Followed by gating on single cells using FSC-AxFSC-H. GFP populations were identified by magnitude of signal in FL1 channel.

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.